The authors suggest that this is due to a decrease of all-trans-retinoic acid (ATRA) during NASH progression, which activates P38, and which, in turn, activates ADAM17 [89]. The gene discussed is ADAM17; the disease is metabolic dysfunction-associated steatohepatitis.